Thomas E. Polen Jr., Chairman, CEO, and President of Becton Dickinson & Co. (NYSE:BDX), reported the sale of 2,764 shares of common stock on June 1, 2026. The transactions, filed with the Securities and Exchange Commission on June 3, 2026, totaled approximately $404,511. The shares were sold at prices ranging from $145.21 to $147.49, with a weighted average sale price of $146.35 per share. The stock currently trades at $145.06, near its 52-week low of $141.82. According to InvestingPro analysis, Becton Dickinson appears undervalued at current levels, with a Fair Value significantly above the market price—placing it among opportunities on the Most Undervalued stocks list.
Prior to the sale, Mr. Polen acquired 20,209 shares of Becton Dickinson common stock through the exercise of stock appreciation rights. These rights, which had an exercise price of $126.16 per share, vested in four annual installments starting November 26, 2017. The award terms were adjusted in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. This acquisition represented a total value of approximately $2,549,567.
Following the acquisition, Mr. Polen disposed of 17,445 shares at a price of $146.15 per share, totaling approximately $2,549,586. This disposal is often associated with tax withholding obligations related to the exercise of equity awards.
The reported transactions were made pursuant to a Rule 10b5-1 plan, which Mr. Polen adopted on March 2, 2026. After these transactions, Mr. Polen’s direct holdings in Becton Dickinson common stock stand at 110,163 shares. For deeper insights into BDX’s valuation and executive compensation trends, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities on InvestingPro. His direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp.
In other recent news, Becton Dickinson (BD) reported its Q2 2026 earnings, surpassing analyst expectations with an adjusted earnings per share (EPS) of $2.90, compared to the forecasted $2.78. The company’s revenue reached $4.7 billion, slightly above the anticipated $4.67 billion. Additionally, BD’s subsidiary, Becton Dickinson Euro Finance S.à r.l., completed an underwritten public offering of €600 million in notes due 2033, with a 3.855% interest rate. These notes are fully guaranteed by BD on a senior unsecured basis.
In product developments, BD launched the Elyra Thulium Fiber Laser System, designed for urologic stone management and soft tissue procedures. The system is available in two configurations to meet different operational needs. Furthermore, BD announced that Peter Menziuso will assume the role of executive vice president and president of BD Interventional starting June 1. Menziuso previously held a leadership position at Johnson & Johnson Vision.
Lastly, BD was among the companies that participated in a roundtable with China’s commerce ministry, alongside other pharmaceutical firms such as Sanofi and Novartis. This meeting aimed to engage with foreign pharmaceutical companies operating in China.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates WAT alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if WAT is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?